Philip Kantoff, MD, is Professor of Medicine at Harvard Medical School. He is also the Chief Clinical Research Officer and Chief of the Division of Solid Tumor Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is the Leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program and Director of the prostate cancer Specialized Program of Research Excellence (SPORE).
Dr. Kantoff is a clinical and translational researcher. He is the principal investigator of a laboratory whose primary focus has been on the genetics and genetic epidemiology of prostate cancer, resistance mechanisms to hormone therapy, and biomarkers relevant as potential prognostic markers and therapeutic targets. His clinical research includes clinical trials, outcomes, and laboratory-based correlative science research.
He is an expert in genitourinary cancers and has also authored numerous articles for peer-reviewed publications such as Cell, Science, Nature, JAMA, The New England Journal of Medicine and. Journal of Clinical Oncology
Dr. Kantoff graduated from Brown University Medical School in Providence, Rhode Island. After completing his internship and residency in internal medicine at New York University Hospital and Bellevue Hospital, both in New York, New York, he spent 4 years at the National Institutes of Health, Bethesda, Maryland, conducting research in gene therapy.